Gómez-Huelgas R, Gómez Peralta F, Rodríguez Mañas L, Formiga F, Puig Domingo M, Mediavilla Bravo J J, Miranda C, Ena J
Servicio de Medicina Interna, Hospital Regional Universitario de Málaga, Málaga, España; Instituto de Investigación Biomédica de Málaga (IBIMA); CIBER de Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III; Sociedad Española de Medicina Interna (SEMI).
Unidad de Endocrinología y Nutrición, Hospital General de Segovia, Segovia, España; Sociedad Española de Diabetes (SED).
Rev Clin Esp (Barc). 2018 Mar;218(2):74-88. doi: 10.1016/j.rce.2017.12.003. Epub 2018 Feb 1.
The prevalence of type 2 diabetes mellitus (DM2) increases markedly with age. Antidiabetic treatment and the objectives of glycaemic control in elderly patients with DM2 should be individualised according to their biopsychosocial characteristics. In elderly patients for whom the benefits of intensive antidiabetic treatment are limited, the basic objectives should be to improve the quality of life, preserve functionality and avoid adverse effects, especially hypoglycaemia. Treatment of DM2 in the elderly was the subject of a consensus document published in 2012 and endorsed by several Spanish scientific societies. Since then, new therapeutic groups and evidence have emerged that warrant an update to this consensus document. The present document focuses on the therapeutic aspects of DM2 in elderly patients, understood as being older than 75 years or frail.
2型糖尿病（DM2）的患病率随年龄增长显著增加。老年DM2患者的抗糖尿病治疗及血糖控制目标应根据其生物心理社会特征进行个体化。对于强化抗糖尿病治疗益处有限的老年患者，基本目标应是改善生活质量、保持功能并避免不良反应，尤其是低血糖。老年DM2的治疗是2012年发表并得到多个西班牙科学学会认可的一份共识文件的主题。自那时以来，出现了新的治疗类别和证据，有必要对该共识文件进行更新。本文件重点关注75岁以上或体弱老年患者DM2的治疗方面。
